<DOC>
	<DOCNO>NCT02712489</DOCNO>
	<brief_summary>A roll-over observational study ( ISS T-003 EF-UP ) conduct extend follow-up volunteer ISS T-003 trial order evaluate persistence vaccine immunogenicity well immunological virological effect induce therapeutic immunization Tat .</brief_summary>
	<brief_title>A Roll-over Observational Study Extended Follow-up Volunteers ISS T-003 Trial</brief_title>
	<detailed_description>An open label , non-interventional study roll-over study ( ISS T-003 EF-UP ) conduct follow-up persistence vaccine humoral response well immunological virological effect induce therapeutic immunization Tat.To aim volunteer ISS T-003 study include one year study , visit week 0 24 54 . To assess anti-Tat humoral immune response determination titration IgM , IgG IgA anti-Tat antibody ( primary endpoint ) evaluate CD4+ T cell count HIV-1 plasma viraemia ( secondary endpoint ) . In addition , depend availability residual specimen ( PBMC , serum plasma ) , laboratory test ( i.e . HIV DNA copy blood ) investigate in-depth immunological virological profile volunteer perform . Physical examination perform monitor clinical status volunteer record appearance clinical sign symptom disease progression well AIDS-defining event , data record related ARV treatment compliance . Pregnancy onset female participant also record .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>previous participation ISS T003 trial without withdrawal consent ; availability participate extend followup study ; sign informed consent . The absence criterion exclude participant study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HAART-treated participant</keyword>
	<keyword>Tat</keyword>
	<keyword>Therapeutic immunization</keyword>
</DOC>